

Analysis of the assortment of antiallergic drugs in Ukraine

¹Kononenko A. V., ¹Lamfannan Saad Eddine, ²Shchokina K. H.

¹National University of Pharmacy, Kharkiv, Ukraine

²Kharkiv Institute of Medicine and Biomedical Sciences, Kharkiv, Ukraine

acya@ukr.net

Allergic diseases are an important clinical problem of medicine. Modern epidemiological data show that today allergic diseases are one of the most common groups of diseases in the world. The incidence is more than 150 million people, and this figure continues to grow. At the same time, the prevalence of allergic diseases in European countries reaches 30%, and about 10% of patients have chronic diseases of allergic genesis.

Currently, pharmacotherapy remains the mainstay of treatment for allergic diseases and includes intranasal glucocorticoids, oral and intranasal antihistamines, and leukotriene receptor antagonists. Mast cell membrane stabilizers are used to prevent certain allergic diseases.

The aim of the study was to analyze the assortment of antiallergic drugs on the pharmaceutical market of Ukraine. The State Register of Medicinal Products of Ukraine and the Compendium of Medicinal Products were used to analyze the assortment of antiallergic drugs. Specific antiallergic drugs were selected for the analysis, namely, H₁-histamine blockers, mast cell membrane stabilizers, and leukotriene receptors antagonists.

It was determined that as of March 1, 2025, 11,784 drugs were registered in Ukraine. Of these, 4,014 were drugs of domestic manufacturers, 7,770 were drugs of foreign companies. 22 international non-patented names (INN) of antiallergic drugs, 221 trade names were registered in Ukraine. Of these, H₁-histamine blockers - 20 INNs, 190 trade names; membrane stabilizers - 2 INNs (3 drugs); leukotriene receptors antagonists - 1 INN (25 trade names), 3 combined drugs. The share of antiallergic drugs is approximately 1.9% of the entire assortment of drugs registered in Ukraine. The leaders among various groups of antiallergic drugs are H₁-histamine

blockers. They account for 86% of all antiallergic drugs registered in Ukraine. Today, representatives of all three generations of H₁-histamine blockers are available in Ukraine. First-generation H₁-histamine receptor blockers are registered – 33 drugs (8 INN), second-generation antihistamines – 59 drugs (8 INN), third-generation H₁-histamine receptor blockers – 98 drugs (3 INN). Thus, the majority of modern antihistamines in Ukraine are representatives of the second and third generations, drugs with a selective mechanism of action that do not suppress the CNS, have a prolonged effect and a high level of safety. The second place is occupied by the youngest antiallergic drugs – leukotriene receptors antagonists (11,3%). It was found that the most popular antiallergic drugs in Ukraine today are third-generation H₁-histamine receptors blockers (98 trade names based on 3 INNs). The leaders in terms of the number of trade names are desloratadine (50 drugs) and levocetirizine (41 drugs). They are slightly inferior to the second-generation antihistaminic drug loratadine (24 drugs) and the leukotriene receptors antagonist montelukast (25 drugs). Combined drugs (3 drugs) contain a fixed combination of active ingredients, namely, montelukast and levocetirizine.

Among the antiallergic drugs registered in Ukraine, 91 (41.2%) are drugs of foreign manufacturers, 130 (58.8%) are foreign drugs. Pharmaceutical companies "Farmak" (20 drugs) and "Zdorovya" (14 drugs) are leaders in Ukraine in the production of antiallergic drugs. Among foreign companies, the leaders are "Adamed" (Poland) (9 drugs), "World Medicine" (Turkey) (8 drugs). Indian pharmaceutical companies ("Micro Labs Ltd", "Hetero Labs Limited", "Dr. Reddy's Laboratories", "Genom Biotech Pvt Ltd", "Sun Pharmaceutical Industries" and others) together produce 35 drugs, which is equal to 15.8% of the entire Ukrainian market of antiallergic drugs.

Thus, the range of drugs for the treatment of allergic diseases on the modern pharmaceutical market of Ukraine is quite wide. 221 drugs based on 22 INNs are registered on the Ukrainian market. The market leader is desloratadine (50 drugs based on it). Levocetirizine is in second place (41 drugs). The range of products of foreign manufacturers exceeds the number of domestic drugs by 1.4 times.